MacroGenics Sells GMP Drug Operations to Bora for $122.5M
MacroGenics and Bora Pharmaceuticals announced that they had entered into a definitive agreement in which MacroGenics will sell its good manufacturing practice, or GMP, drug substance manufacturing operations to Bora, subject to customary closing conditions. Under the terms of the asset purchase agreement, Bora will pay MacroGenics an upfront payment of $122.5M, before transaction fees and expenses. Upon closing, Bora will assume responsibility for MacroGenics' manufacturing operations supporting clinical and commercial production. Both the Rockville, Maryland headquarters site, including the FDA-approved facility with total capacity of 11,000 liters, and Frederick, Maryland warehouse will transfer to Bora. In addition, approximately 140 MacroGenics employees are expected to be hired by Bora. The companies will jointly work to ensure a transition and continued service for both MacroGenics and any existing CDMO client. As part of the transaction, MacroGenics will have a supply arrangement with Bora to support process development and drug substance production for its internal pipeline needs. The transaction is expected to close in the third quarter of 2026, subject to the satisfaction or waiver of customary closing conditions.
